[go: up one dir, main page]

BR0315140A - Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação - Google Patents

Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação

Info

Publication number
BR0315140A
BR0315140A BR0315140-9A BR0315140A BR0315140A BR 0315140 A BR0315140 A BR 0315140A BR 0315140 A BR0315140 A BR 0315140A BR 0315140 A BR0315140 A BR 0315140A
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
warm
treating cancer
blooded animal
Prior art date
Application number
BR0315140-9A
Other languages
English (en)
Inventor
Francis Thomas Boyle
Jon Owen Curwen
Neil James Gallagher
Ursula Joy Hancox
Andrew Mark Hughes
Donna Johnstone
Sian Tomiko Taylor
David William Tonge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0315140A publication Critical patent/BR0315140A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçãO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DO CâNCER EM UM ANIMAL DE SANGUE QUENTE, E, USO DE UMA COMBINAçãO". é descrita uma combinação, compreendendo um antagonista de receptor de endotelina, ou um sal farmaceuticamente aceitável do mesmo, e um EGFR TK1, ou um sal farmaceuticamente aceitável do mesmo.
BR0315140-9A 2002-10-12 2003-10-07 Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação BR0315140A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (1)

Publication Number Publication Date
BR0315140A true BR0315140A (pt) 2005-08-16

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315140-9A BR0315140A (pt) 2002-10-12 2003-10-07 Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação

Country Status (29)

Country Link
US (1) US20060122180A1 (pt)
EP (1) EP1553950B1 (pt)
JP (1) JP2006510605A (pt)
KR (1) KR20050056238A (pt)
CN (1) CN100342853C (pt)
AR (1) AR041595A1 (pt)
AT (1) ATE369136T1 (pt)
AU (1) AU2003269259B2 (pt)
BR (1) BR0315140A (pt)
CA (1) CA2501959A1 (pt)
CY (1) CY1107605T1 (pt)
DE (1) DE60315490T2 (pt)
DK (1) DK1553950T3 (pt)
ES (1) ES2289316T3 (pt)
GB (1) GB0223854D0 (pt)
IS (1) IS2473B (pt)
MX (1) MXPA05003808A (pt)
MY (1) MY135441A (pt)
NO (1) NO20051658L (pt)
NZ (1) NZ539137A (pt)
PL (1) PL375584A1 (pt)
PT (1) PT1553950E (pt)
RU (1) RU2005114487A (pt)
SA (1) SA04240502B1 (pt)
TW (1) TW200412971A (pt)
UA (1) UA82492C2 (pt)
UY (1) UY28017A1 (pt)
WO (1) WO2004035057A1 (pt)
ZA (1) ZA200502874B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
RU2412941C2 (ru) * 2006-03-13 2011-02-27 Инсайсив Фармасьютикалз, Инк. Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида
NZ585310A (en) * 2007-10-12 2012-02-24 Astrazeneca Ab Composition 064
ES2543280T3 (es) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
AU2022297082B2 (en) * 2021-06-22 2024-04-18 Alchemedicine, Inc. Compound, endothelin A receptor antagonist and pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
PL196940B1 (pl) * 1998-04-29 2008-02-29 Osi Pharmaceuticals Bezwodna postać i monohydrat mesylanu N-(3-etynylofenylo)-6,7-bis (2-metoksyetoksy)-4-chinazolinaminy
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
IS7825A (is) 2005-04-26
AR041595A1 (es) 2005-05-26
DE60315490T2 (de) 2008-05-08
HK1078784A1 (en) 2006-03-24
US20060122180A1 (en) 2006-06-08
PL375584A1 (en) 2005-11-28
DK1553950T3 (da) 2007-10-15
EP1553950B1 (en) 2007-08-08
UA82492C2 (uk) 2008-04-25
NO20051658L (no) 2005-05-06
UY28017A1 (es) 2004-04-30
CA2501959A1 (en) 2004-04-29
SA04240502B1 (ar) 2008-09-14
NZ539137A (en) 2008-01-31
JP2006510605A (ja) 2006-03-30
RU2005114487A (ru) 2006-02-10
AU2003269259A1 (en) 2004-05-04
ES2289316T3 (es) 2008-02-01
CY1107605T1 (el) 2013-03-13
KR20050056238A (ko) 2005-06-14
TW200412971A (en) 2004-08-01
CN100342853C (zh) 2007-10-17
PT1553950E (pt) 2007-09-26
MY135441A (en) 2008-04-30
WO2004035057A1 (en) 2004-04-29
EP1553950A1 (en) 2005-07-20
IS2473B (is) 2008-12-15
DE60315490D1 (de) 2007-09-20
ZA200502874B (en) 2006-02-22
MXPA05003808A (es) 2005-06-08
AU2003269259B2 (en) 2007-03-15
ATE369136T1 (de) 2007-08-15
CN1703224A (zh) 2005-11-30
GB0223854D0 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
ATE541860T1 (de) Humane antikörper gegen cd40 zur therapie von b- zell tumoren
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
DK1509521T3 (da) 1H-Imidazol[4,5-c]quinolinderivater til behandling af proteinkinaseafhænige sygdomme
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0206985A (pt) Anticorpos modificados e métodos de uso
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
CY1113894T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη
IS2259B (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE60313754D1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
BR0108865A (pt) Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
BR0113646A (pt) Tratamento de distúrbios inflamatórios
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
DK1161254T3 (da) Behandling af autoimmune sygdomme med en ekstrakt af amerikansk ginseng

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.